Fioravanti A, et al. - IInvestigators ascertained the potential impact of intravenous (IV) tocilizumab (TCZ) (an interleukin-6 receptor antagonist) on serum levels of leptin, adiponectin, resistin, visfatin, and chemerin among 44 patients with rheumatoid arthritis (RA). They observed ESR, CRP, DAS28-ESR, and HAQ were significantly improved in those receiving TCZ as monotherapy or combined with MTX at the end of the follow-up. A significant increase in total cholesterol was noticed in the lipid profile. In those treated with TCZ monotherapy or combined therapy, they reported a significant decrease of chemerin and increased adiponectin with no significant associations with clinical and biochemical parameters.